FDAnews Drug Daily Bulletin
Pharmaceuticals / Postmarket Safety

Suspensions, Recalls of Ranitidine Products Continue to Expand

Oct. 14, 2019
A A

Walgreens and Rite Aid joined CVS in suspending sales of ranitidine products amid concerns over contamination of the heartburn drugs with a probable carcinogen, N-nitrosodimethylamine (NDMA).

CVS Health said it was exerting “an abundance of caution” in its move to stop sales of Zantac (ranitidine) and its own ranitidine generics, although the products have not been recalled and the FDA hasn’t directed patients to stop taking them.

Walgreens and Rite Aid also moved to put sales of the products on pause, saying they’re taking Zantac and ranitidine generics off their shelves while testing takes place.

The latest actions follow the FDA’s warning that it found low levels of NDMA in Zantac and other ranitidine products.

View today's stories